Pihlajalinna’s Q3 ramp-up costs were larger than expected, but Q4 should already show a clear y/y EB...
Redeye comments on Annexin’s Q3 report, which came in as expected, and largely reiterate our view of...
NoHo Partners will report its Q3 on 8 November. We are 1% below Refinitiv consensus on the top line ...
Redeye maintains its positive view of Orexo after the Q3 report.
Small estimate changes in ’22e-‘24e Solid demand for CSP and strong net leasing Refinancing secures ...
Q3 report due Friday, 11 November We reduce ’23e-’24e sales by 3-1% Balance sheet set for growth aft...
Q3 due on Wednesday, 9 November Sale of Kölvallen the key EBIT driver Share trading at ~3x adj.
Techtum står idag för ca 90 % av Bolagets omsättning och är en etablerad distributör av medicintekni...
Redeye remains optimistic about OXE Marine following the Q3 report.
Based on segment reporting, Taaleri reported Q3 sales of EUR 26.
Nya avtal i Q3 Nettoomsättningen för Q3 uppgick till 1,4 mkr (1,8 mkr).
Åter på nivåer från innan pandemin Arcomas omsättning för Q3 uppgick till 29 mkr, motsvarande en til...
Exel’s Q3 results didn’t meet our estimates, but long-term EBIT potential remains significant even i...
Fram Skandinavien’s local digital brands are growing rapidly.
Investment portfolio earnings the only disturbance… …in another solid quarter from BankNordik Mid-ra...
Q3 beat driven by Investment Management AUM and postponed divestments lift ’23-24 EBIT 2023e EV/EBIT...
Sales in line with ABGSCe, EBIT beat by 20% Estimates raised for Q4, minor revisions for ‘23e & ‘24e...
Obducat fortsätter att vinna fler affärer, där orderingången under årets tredje kvartal uppgick till...
Redeye is overall positive to the second interim analysis from Vicore’s phase II trial in IPF with d...
Taaleri reported Q3 EBIT of EUR 18.5m, coming clearly below Refinitiv consensus at EUR 14.
